Sientra (SIEN) Downgraded to “Sell” at BidaskClub
Sientra (NASDAQ:SIEN) was downgraded by investment analysts at BidaskClub from a “hold” rating to a “sell” rating in a research note issued on Tuesday.
Several other brokerages also recently issued reports on SIEN. Canaccord Genuity reaffirmed a “buy” rating and issued a $14.00 price target on shares of Sientra in a report on Sunday, October 8th. Stifel Nicolaus reaffirmed a “hold” rating and issued a $14.00 price target (up previously from $11.00) on shares of Sientra in a report on Wednesday, September 27th. Zacks Investment Research raised shares of Sientra from a “sell” rating to a “hold” rating in a report on Tuesday, January 2nd. ValuEngine raised shares of Sientra from a “sell” rating to a “hold” rating in a report on Sunday, December 31st. Finally, William Blair raised shares of Sientra from a “market perform” rating to an “outperform” rating in a report on Wednesday, September 13th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and four have given a buy rating to the company. The company has an average rating of “Hold” and an average target price of $15.00.
Shares of Sientra (NASDAQ SIEN) opened at $13.55 on Tuesday. Sientra has a fifty-two week low of $7.20 and a fifty-two week high of $16.68. The stock has a market cap of $262.81, a PE ratio of -4.75 and a beta of -1.47. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.87 and a quick ratio of 1.92.
Sientra (NASDAQ:SIEN) last announced its quarterly earnings results on Tuesday, November 7th. The medical instruments supplier reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.68) by ($0.06). Sientra had a negative net margin of 169.77% and a negative return on equity of 68.82%. The business had revenue of $9.80 million during the quarter, compared to analysts’ expectations of $10.54 million. During the same period last year, the company earned ($0.55) EPS. The firm’s revenue for the quarter was up 50.8% on a year-over-year basis. equities research analysts expect that Sientra will post -3.23 EPS for the current fiscal year.
Large investors have recently bought and sold shares of the company. JPMorgan Chase & Co. acquired a new position in shares of Sientra in the second quarter valued at approximately $101,000. Nationwide Fund Advisors raised its position in shares of Sientra by 260.4% in the second quarter. Nationwide Fund Advisors now owns 10,963 shares of the medical instruments supplier’s stock valued at $107,000 after buying an additional 7,921 shares during the last quarter. New York State Common Retirement Fund acquired a new position in shares of Sientra in the second quarter valued at approximately $148,000. Rhumbline Advisers acquired a new position in shares of Sientra in the second quarter valued at approximately $158,000. Finally, Dimensional Fund Advisors LP raised its position in shares of Sientra by 23.4% in the second quarter. Dimensional Fund Advisors LP now owns 18,660 shares of the medical instruments supplier’s stock valued at $181,000 after buying an additional 3,534 shares during the last quarter. 76.63% of the stock is owned by institutional investors and hedge funds.
Sientra, Inc is a medical aesthetics company. The Company’s primary products are silicone gel breast implants for use in breast augmentation and breast reconstruction procedures, which it offers in over 190 variations of shapes, sizes and textures. The Company sells its breast implants and breast tissue expanders, or breast products to plastic surgeons.
Receive News & Ratings for Sientra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra and related companies with Analyst Ratings Network's FREE daily email newsletter.